Drug FDA Class II Ongoing Contamination / non-sterility
CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Chiesi USA, Inc. Published Apr 1, 2026
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 60/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Chiesi USA, Inc. or your place of purchase with questions, and see the source record below for full details.
Reason for recall
Lack of Assurance of Sterility
Hazards
Lack of Sterility Assurance · primary
Affected products (1)
CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
CUROSURF · 7,235 vials
NDC: 10122-510, 10122-510-03, 10122-510-01
Code info: Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26.
Affected areas
Nationwide
Timeline
- InitiatedMar 17, 2026
- PublishedApr 1, 2026
- Recall number
- D-0402-2026
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.